The Fifty-fourth World Health Assembly,Recalling resolutions, nominally WHA39.27, WHA41.16, WHA43.20, WHA45.27,WHA47.12, WHA47.16, WHA47.17, WHA49.14 and WHA52.19;Having considered the report on the revised drug strategy and bearing in mind the previousreport on the subject that highlight challenges related to international trade agreements, access toessential drugs, drug quality and rational use of medicines, together with the urgent need to improveaccess to drugs for treating priority health problems such as malaria, childhood illnesses, HIV / AIDSand tuberculosis, among others;Acknowledging the four main objectives of WHOs medicines strategy, namely, to frame andimplement policy; to ensure access; to ensure quality, safety and efficacy; and to promote rational useof medicines;Taking into account that the aforementioned health problems are particularly acute among poorand vulnerable populations, entrapping them in poverty, and substantially inhibiting the growth ofnational and international economies to the detriment of all humanity;Recalling that the Constitution of the World Health Organization provides that the enjoyment ofthe highest attainable standard of health is one of the fundamental rights of every human being withoutdistinction of race, religion, political belief, economic or social condition, and considering thatprogressive realization of that right should involve access, ona non-discriminatory basis, to healthfacilities, prevention, care, treatment and support in the context of access to medicines;Bearing in mind the WHO global framework for expanding access to essential drugs, and itsfour components: the rational selection and use of medicines, reliable health and supply systems,sustainable financing, and affordable prices;Taking into account that access to medicines is particularly price sensitive, since most people indeveloping countries have to pay personally for health care, and that the commitment of governments, 1 Document A54 / 17.2 Document A53 / 10.WHA54.112organizations of the United Nations system, the private sector, and the civil society is necessary inorder to achieve universal access;1Taking into account the urgency of implementing the WHO medicines strategy in order fully torealize the enormous health benefits that essential drugs can offer to the one-third of the humanpopulation now lacking them;Taking into account the need to increase the current levels of international technical andeconomic assistance channeled to implementation of the WHO medicines strategy;Recognizing the importance of national drug policies established inaccordance with WHOguidelines;Commending the strong leadership that WHO has shown in re-emphasizing the essential drugsconcept, and the contribution of nongovernmental organizations working in public health to attainingsuch objectives as the framing of national drug policies and related aspects;Noting that the impact of international trade agreements on access to, or local manufacturing of,essential drugs and on the development of new drugs needs tobe further evaluated;Recognizing that well-functioning and equitable health systems, including reliable supplysystems, are key elements in any framework for expanding access to essential drugs;Noting resolution 2001 / 33 on access to medication in the context of pandemics such asHIV / AIDS adopted by the United Nations Commission on Human Rights at its 57th session;1. URGES Member States:(1) to reaffirm their commitment to ensuring public health interests and to make every effortto promote equitable access to medicines, and to undertake the necessary action within theirnational health policies, including for priority diseases and pandemics, as an important elementfor progressively achieving the highest attainable standard of health;(2) to take effective measures inaccordance with international law and internationalagreements acceded to in order to ensure improved access to medicines;(3) to cooperate with respect to resolution 2001 / 33 of the United Nations Commission onHuman Rights;(4) to pursue measures directed to expanding access of their populations to essential drugs,including the implementation of resolution WHA52.19 taking into account the cost-effectiveness of rational drug use aswell as affordability;(5) in order to increase access to medicines, and inaccordance with the health needs ofpeople, especially those who can least afford the costs, and recognizing the efforts of MemberStates to expand access to drugs and promote domestic industry, cooperate constructively instrengthening pharmaceutical policies and practices, including those applicable to generic drugs, 1 Globalization, TRIPS and access to pharmaceuticals. WHO Policy Perspectives on Medicines, No. 3, March, 2001.Geneva: WHO (document WHO / EDM / 2001.2).WHA54.113and intellectual property regimes in order further to promote innovation and the development ofdomestic industries, consistent with applicable international law;(6) to provide financial support and technical cooperation to enable Member States in need toexpand access of their populations to essential drugs;2. REQUESTS the Director-General:(1) jointly with Member States, nongovernmental organizations and other partners involvedin public health, to keep under review the effectiveness of the current strategy for essentialdrugs, and to stimulate the development of drugs for diseases whose burden lies predominantlyin poor countries;(2) to explore the feasibility and effectiveness of implementing, in collaboration withnongovernmental organizations and other concerned partners, systems for voluntary monitoringdrug prices and reporting global drug prices with a view to improving equity in access toessential drugs in health systems, and to provide support to Member States in that regard;(3) to provide support for implementation of drug monitoring systems in order better toidentify development of resistance, adverse reactions and misuse of drugs within health systems,thus promoting rational use of drugs;(4) to continue and to enhance efforts to study and report on existing and future healthimplications of international trade agreements inclose cooperation with relevantintergovernmental organizations;(5) to provide enhanced support to Member States that need and request support in achievingthe priorities setout in the WHO medicines strategy;(6) to provide support to Member States to setup efficient national regulatory mechanismsfor quality assurance that will help ensure compliance with good manufacturing practices,bioavailability and bioequivalence;(7)to continue WHO s work in the field of traditional medicines;(8) to report to the Fifty-fifth World Health Assembly on the progress of initiatives taken,globally or regionally, to expand access to essential drugs.Eighth plenary meeting, 21 May 2001A54 / VR / 8= = =